Kidney Cancer

The approval was based on data from the pivotal phase 3 CheckMate-9ER trial.

Dr. Primo Lara, Jr., executive associate dean for Cancer Programs, School of Medicine, at UC Davis Comprehensive Cancer Center, highlights the need for personalized medicine using multidisciplinary care for patients with renal cell carcinoma.

Tivozanib is approved by the FDA for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma who have received 2 or more prior systemic therapies.

Tivozanib is approved by the FDA for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma who have received 2 or more prior systemic therapies.

The FDA is scheduled to decide on the new drug application by September 15, 2021.

Following the recent FDA approval of tivozanib in renal cell carcinoma (RCC), the VEGF-TKI is now being explored in combination with the PD-1 inhibitor nivolumab in the phase 3 TiNivo-2 trial in patients with relapsed/refractory RCC.

The FDA has approved tivozanib for kidney cancer.

The combination regimen shrank tumors and led to disease control in the majority of patients.

An expert panel discusses the case of a 65-year-old Caucasian male who is noted to have an incidental 3-cm right renal mass, enhancing on a contrasted CT scan as part of a routine follow-up for his metastatic castration-resistant prostate cancer, diagnosed in 2017 and currently undergoing therapy.

The European Commission is reviewing data from the pivotal phase 3 CheckMate-9ER trial.

Adding the off-the-shelf, cell-based immunotherapy ilixadencel to frontline sunitinib was associated with an overall survival benefit in patients with metastatic renal cell carcinoma.

The study assessed factors associated with survival outcomes in patients with metastatic clear cell renal cell carcinoma receiving immune checkpoint inhibitors.

Published data show the PD-1 inhibitor induced strong antitumor activity in patients with both advanced clear cell renal cell carcinoma (ccRCC) and advanced non-ccRCC.

The phase 3 ZIRCON trial is assessing TLX250-CDx as a noninvasive tool to identify clear cell renal cell carcinoma in patients with indeterminate renal masses.

The approval is based on data from the phase 3 CheckMate-9ER trial.

Register for a live, interactive event featuring leaders in oncology reviewing and discussing patient cases in Bladder Cancer/Renal Carcinoma.

A large review showed that cancer specific survival was improved in overweight and obese patients with renal cell carcinoma compared with patients with normal BMI.

Combining telaglenastat with cabozantinib did not improve outcomes versus cabozantinib alone in a phase 2 trial.

Improvements in technology have renewed interest in the technique.

Recent research has revived the controversy regarding the role of cytoreductive nephrectomy in this setting.

Rana R. McKay, MD, highlights developments with immunotherapy and targeted agents in the treatment paradigm for non-clear cell renal cell carcinoma.

Findings from the phase 3 KEYNOTE-581/CLEAR trial (Study 307) showed that the combination improved overall survival, progression-free survival, and response versus sunitinib.

"There is unmet medical need in trying to determine if there is a differential benefit to using one therapy over another in the non-clear cell setting," Thomas E. Hutson, DO, PharmD.

Among a small group of patients with metastatic renal cell carcinoma who developed acute interstitial nephritis while on immune checkpoint therapy, 100% had a durable response to treatment.

At a median follow-up of over 2.5 years, the combination continued to show a significant benefit in overall and progression-free survival versus single-agent sunitinib.